Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment

Abstract

Aim: The increased risk of hepatocellular carcinoma (HCC) recurrence in hepatitis C virus (HCV)-infected patients treated with direct-acting antivirals (DAAs) after curative treatment for HCC is controversial. The purpose of this study was to examine the risk of HCC recurrence after DAA therapy.

Methods: We conducted a retrospective cohort study of 312 consecutive patients with HCV-related HCC who received DAA therapy in participating institutions between September 2014 and July 2016. All patients received curative hepatectomy or radio-frequency ablation. We calculated the annual incidence of HCC recurrence after DAA therapy and identified the risk factors for HCC recurrence using Cox regression models.

Results: The median age was 74 years old, and a sustained virological response was achieved by 288 patients. The 3-year-overall survival rate was 95.4% in a median follow-up period of 855 days. HCC recurred in 135 patients. The 1-, 2- and 3-year recurrence rates were 18.3%, 38.8% and 55.4%, respectively. A multivariate analysis revealed that the following factors were associated with HCC recurrence: multiple tumors at the first HCC treatment [hazard ratio (HR) = 2.21; 95%CI: 1.41-3.49], a history of multiple treatments for HCC (HR = 1.97; 95%CI: 1.28-3.02), and α-fetoprotein (AFP-L3) ≥ 10% at the initiation of DAA therapy (HR = 4.74; 95%CI: 2.10-10.7).

Conclusion: Among patients treated with DAAs after the curative treatment of HCC, multiple tumors at the first HCC treatment, multiple prior HCC treatments and a high AFP-L3 level before DAA therapy were associated with recurrence, and the rate of recurrence was comparable to that before the DAA era.

Keywords

Hepatocellular carcinoma / hepatitis C virus / direct-acting antiviral / recurrence

References

[1] Torre LA,Siegel RL,Lortet-Tieulent J.Global cancer statistics, 2012..CA Cancer J Clin2015;65:87-108

[2] CBD 2013 Mortality and Causes of Death CollaboratorsGlobal, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013..Lancet2015;385:117-71 PMCID:PMC4340604

[3] Kanwal F,Kramer JR,Goetz MB.Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection..Gastroenterology2011;140:1182-8 PMCID:PMC3073667

[4] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatology2016;65:719-26

[5] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[6] Waziry R,Grebely J,Law M.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy:a systematic review, meta-analyses, and meta-regression..J Hepatol2017;67:1204-12

[7] Nagata H,Asahina Y,Asano Y.Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C..J Hepatol2017;67:933-9

[8] Romano A,Piovesan S,Anastassopoulos G.Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study..J Hepatol2018;69:345-52

[9] Ikeda K,Kobayashi M,Fujiyama S.Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma..Dig Dis Sci2017;62:2932-42

[10] ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: [e-mail]1Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts..J Hepatol2016;65:734-40

[11] Huang AC,Dodge JL,Terrault NA.Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout..Hepatology2018;68:449-61 PMCID:PMC6097892

[12] Ooka Y,Shuntaro O,Ogasawara S.Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection..Hepatol Int2018;12:523-30

[13] Minami T,Nakagomi R,Sato M.The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma..J Hepatol2016;65:1272-3

[14] Emamaullee JA,Meeberg G,Bain VG.HCV eradication with direct-acting antivirals does not impact HCC progression on the waiting list or HCC recurrence after liver transplantation..Can J Gastroenterol Hepatol2019;2019:2509059 PMCID:PMC6354133

[15] Zanetto A,Vitale A,Ferrarese A.Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals..Liver Transpl2017;23:1103-12

[16] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma..J Hepatol2017; PMCID:PMC5837901

[17] Claudon M,Choi BI,Kudo M.Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS..Ultrasound Med Biol2013;39:187-210

[18] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[19] Toshimori J,Nakamura S,Morimoto Y.Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location..Acta Med Okayama2015;69:219-26

[20] Kim YS,Rhim H,Choi D.Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors..J Hepatol2013;58:89-97

[21] Dohi C,Miyahara K,Wada N.Potential of alpha-fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma..Hepatol Res2016;46:916-23

[22] Nouso K,Nakamura S,Takayama H.Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein..J Gastroenterol Hepatol2011;26:1195-200